Galectin Thera: GALT

Galectin Therapeutics Inc (NASDAQ: GALT) is developing medical therapies for liver fibrosis and cancer by targeting galectin proteins

[Galectin Thera: GALT @GalectinGALT]

Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant. https://t.co/pFuu4648i6

[Galectin Thera: GALT @GalectinGALT]

UPDATE: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 https://t.co/zy3srOVBOD

[Galectin Thera: GALT @GalectinGALT]

We are excited to announce we will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases @AASLDtweets next week.

Read more: https://t.co/mHV9tmEKvc

[Galectin Thera: GALT @GalectinGALT]

Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment.

Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant. https://t.co/C6Dwg1Q6mC

[Galectin Thera: GALT @GalectinGALT]

Galectin will share five scientific presentations at The Liver Meeting 2022, hosted by @AASLDtweets this weekend. Get a preview of the abstracts at the link below. We look forward to seeing everyone attending AASLD. https://t.co/UHzcuXKFUb

[Galectin Thera: GALT @GalectinGALT]

A live webcast of the discussion will be available at the link below: https://t.co/MQvfGQstWV

[Galectin Thera: GALT @GalectinGALT]

On 10/17/22, Galectin will present in the H.C. Wainwright 6th Annual NASH Investor Conference.

Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation at the conference. https://t.co/6AB33YvIaU

[Galectin Thera: GALT @GalectinGALT]

“This second IND is a significant milestone and exemplifies the dedication of our team towards furthering development of belapectin to better the lives of patients in a variety of important diseases." — Joel Lewis, President and CEO of Galectin Therapeutics

[Galectin Thera: GALT @GalectinGALT]

NEW: Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
https://t.co/4FoJJTYXBk

[Galectin Thera: GALT @GalectinGALT]

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
https://t.co/kZcR0miboV

[Galectin Thera: GALT @GalectinGALT]

Currently, there is no treatment for fatty liver disease other than diet & exercise, which are only somewhat effective in early stages of the disease. Which is why our clinical trial to develop a treatment for the late stages of this disease is so crucial.https://t.co/5P0RHcQ1Sh

[Galectin Thera: GALT @GalectinGALT]

With a staggering 80 to 100 million Americans affected, our clinical study exploring a new treatment for the late stages of the disease that can lead to liver failure is an important step forward.

[Galectin Thera: GALT @GalectinGALT]

With increasing frequency, doctors have seen ultrasound results demonstrating “fatty liver” in patients. https://t.co/adqJLYf3YB

[Galectin Thera: GALT @GalectinGALT]

With increasing frequency, doctors have seen ultrasound results demonstrating “fatty liver” in patients. https://t.co/adqJLYf3YB

[Galectin Thera: GALT @GalectinGALT]

Interested in participating in the trial? Click here to see if you qualify and to learn more https://t.co/xWZNLtIeXi

[Galectin Thera: GALT @GalectinGALT]

Curious to know the process of GALT’s Phase 2b/3 NAVIGATE Study? Here’s a thread with what you need to know 👇

[Galectin Thera: GALT @GalectinGALT]

👩‍⚕️ After an additional 18-months of treatment, doctors will perform another endoscopy

📊 Finally, the results of both phases of the trial will be analyzed to determine if belapectin should become an approved therapy for NASH cirrhosis

[Galectin Thera: GALT @GalectinGALT]

NASH #cirrhosis will soon become the number one reason for #liver transplants. $GALT is conducting research to change that in its NAVIGATE Study, the only adaptive Phase 2b/3 clinical trial focused on #NASH cirrhosis. Learn more here: https://t.co/dpo2xWVzXf